Literature DB >> 3388046

Type-restricted neutralization of molecular clones of human immunodeficiency virus.

D J Looney1, A G Fisher, S D Putney, J R Rusche, R R Redfield, D S Burke, R C Gallo, F Wong-Staal.   

Abstract

In a study of the immunologic significance of the genetic diversity present within single isolates of human immunodeficiency virus type 1 (HIV-1), the neutralization of viruses derived from molecular clones of the HIV-1 strain HTLV-IIIB by an extensive panel of sera was compared. Sera from HIV-1-infected patients and from goats immunized with polyacrylamide gel-purified HIV-1 envelope glycoprotein (gp120), native gp120, or gp120-derived recombinant peptides, showed marked heterogeneity in neutralizing activity against these closely related viruses. The change of a single amino acid residue in gp120 may account for such "clonal restriction" of neutralizing activity.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3388046     DOI： 10.1126/science.3388046

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  31 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.

Authors:  W A Marasco; J Bagley; C Zani; M Posner; L Cavacini; W A Haseltine; J Sodroski
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

3.  Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; T Ryskamp; N Haigwood; R Newman; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

Review 4.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

5.  Neutralizing antibodies and antigens in AIDS.

Authors:  S G Norley; R Kurth
Journal:  Infection       Date:  1991       Impact factor: 3.553

6.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.

Authors:  N Kato; H Sekiya; Y Ootsuyama; T Nakazawa; M Hijikata; S Ohkoshi; K Shimotohno
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.